Introduction
Leading pharmaceutical company received DCGI approval to manufacture and market generic semaglutide injection, Noveltreat, for chronic weight management in adults after patent expiry in India.
Also Read: Ceinsys Tech stock rallies 5% after bagging ₹12.21 Cr municipal work order
Share price movement of Sun Pharma
On January 23, 2026, Sun Pharmaceutical Industries Limited opened at ₹1,640.15, up 0.35% from its previous close of ₹1,634.40. The stock reached a high of ₹1,640.20 (0.36%) and a low of ₹1,625.30. By 11:30 AM, it traded at ₹1,631.30, a -0.19% decrease, with a market cap of ₹3,91,394.29 crore.
Sun Pharma Receives DCGI Approval for Generic Semaglutide Injection
Sun Pharmaceutical Industries Limited received approval from the DCGI to manufacture and market generic semaglutide injection in India for chronic weight management in adults.
The product, named Noveltreat, will launch after the expiry of semaglutide patent. It follows a Phase III clinical trial conducted in India. Five dose strengths will be available.
Noveltreat is administered via a prefilled pen with weekly maintenance dose of 2.4 mg. Sun Pharma had earlier received approval for semaglutide for type 2 diabetes under the brand Sematrinity.
Stock performance of Sun Pharma for Period of 1 week, 6 months, and 1 year
Sun Pharmaceutical Industries Limited delivered a -2.08% return over the past week, declined by -3.81% in the past 6 months, and fell -10.9% over the past 1 year.
Also Read: Cupid Ltd jumps 6% as company to invest ₹331.53 Cr in Baazar Style Retail, know why
Shareholding pattern of Sun Pharma
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 54.50% | 54.50% | 54.50% |
| FII | 16.10% | 16.60% | 17.30% |
| DII | 20.80% | 20.20% | 19.50% |
| Public | 9% | 9% | 8.50% |
About Sun Pharma
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) is India’s largest pharmaceutical company, manufacturing and marketing branded and generic formulations, APIs, with global facilities and operations across international markets.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Sun Pharmaceutical Industries Limited share price rising today?
A: Sun Pharmaceutical Industries Limited received DCGI approval to manufacture and market generic semaglutide injection, Noveltreat, for chronic weight management in India.
Q: What is Sun Pharmaceutical Industries Limited’s main business focus?
A: Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharma Ingredients (APIs) globally.
Q: What is the 52-week high and low of Sun Pharmaceutical Industries Limited stock?
A: Sun Pharmaceutical Industries Limited stock’s 52-week high is ₹1,850.95 and the 52-week low is ₹1,547.25.


